



Reliable tuberculosis blood testing for your immunocompromised patients

The T-SPOT®.TB test is a unique, single-visit blood test for tuberculosis (TB) that offers the opportunity to detect latent TB before it activates. The test is effective with immunocompromised and BCG-vaccinated patient populations and is the only IGRA without a warning or limitation for screening immunocompromised individuals.¹

Immunocompromised patients have an increased risk for TB

Many conditions and treatments can weaken an individual's immune system, making them immunocompromised. Those with compromised immune systems face a higher risk of contracting TB and a higher risk of latent tuberculosis infection (LTBI) becoming active.²

T-SPOT®.TB: reliable TB testing in the immunocompromised

T-SPOT®.TB is the only TB test with sensitivity and specificity >95%¹—an accuracy that allows clinicians to confidently screen and detect TB infection in challenging patient populations including the immunocompromised. The test uses a proprietary enumeration process that includes washing, counting, and standardizing the number of T-cells in each specimen, an innovative approach that produces results physicians and patients can trust.

- Mitigates the risk that low T-cell count will impact patient results. This is especially critical in immunocompromised patients, including those receiving immunosuppressive therapy
- Utilizes a standard number of PBMCs (peripheral blood mononuclear cell) to correct for a patient's immune status
- Removes background interferon-gamma to maximize sensitivity (estimated sensitivity: 95.6%) and specificity (estimated specificity: 97.1%)¹
- Consistent results with repeat testing in healthcare workers³

Identifying those at risk

The Centers for Disease Control and Prevention (CDC) has identified the following persons with medical conditions that weaken the immune system and make them at higher risk for developing active TB disease^{4,5}:

- HIV infection (the virus that causes AIDS)
- Substance abuse
- Silicosis
- Diabetes mellitus
- Severe kidney disease
- Low body weight
- Organ transplants
- Head and neck cancer
- Medical treatments such as corticosteroids or organ transplant
- Specialized biologic/biosimilar treatment for rheumatoid arthritis, plaque psoriasis, and inflammatory bowel disease including Crohn disease and ulcerative colitis among other autoimmune disease

Guidelines for biologic/biosimilar treatment

Administering biologic treatment causes suppression of the immune system, making those patients undergoing treatment more susceptible to infection.⁶ Screening for latent infections like tuberculosis (TB) and other infections like hepatitis is recommended by a number of leading health organizations.^{7,8}

The American College of Rheumatology (ACR) and American College of Gastroenterology (ACG) recommend screening for hepatitis B (HBV), hepatitis C (HCV), and latent TB infection in patients starting or currently receiving certain biologic agents.⁷⁻⁹

It's easy to order T-SPOT®.TB

Streamline ordering T-SPOT®.TB using code 37737:

- **Efficient:** Help to improve efficiency with faster ordering, reduced paperwork, and straightforward billing process
- **Timely:** Get electronic test results reports as soon as they are available
- **Accessible:** T-SPOT®.TB is available through our access to a national network of more than 2,200 Patient Service Centers (PSCs). All of our Patient Service Centers have implemented the Peace of Mind program with enhanced safety features consistent throughout the day for all patients
- **Convenient:** You can order T-SPOT®.TB online through Quanam® Lab Services Manager or your EHR

Make sure T-SPOT®.TB test information (test code 37737) is added to your EHR.

Test order information

Test code	Test name	Specimen type	CPT code
37737	T-SPOT®.TB	1 Quest-provided green-top 9 mL lithium heparin tube ^a	86481
94345	Hepatitis C Antibody with Reflex to HCV RNA, PCR w/Reflex to Genotype, LiPA®	2.5 mL serum collected in each of 2 Serum Separator Tubes (SST®)	86803
498	Hepatitis B Surface Antigen with Reflex Confirmation	2 mL serum	87340
8475	Hepatitis B Surface Antibody Immunity, Quantitative	1 mL serum	86317
37676	Hepatitis B Core Antibody, Total, with Reflex to IgM	1 mL serum	86704

^a Specimen requirements for children: <2 years: 2 mL lithium heparin; 2-10 years: 4 mL lithium heparin; ≥10 years: 6 mL lithium heparin.

Tube kits and shipping kits are available by emailing TSPOT@QuestDiagnostics.com with your Quest account number or by calling 1.877.598.2522. Note: shipping kits and tube kits will be automatically replenished.

Detailed test information is available at TestDirectory.QuestDiagnostics.com

Learn more about the benefits of TB blood testing at TBBloodTesting.com or contact your local Quest Diagnostics sales representative at 1.866.MYQUEST (1.866.697.8378)

T-SPOT®.TB is approved by the USFDA.

The T-SPOT®.TB test is an in vitro diagnostic test for the detection of effector T-cells that respond to stimulation by *Mycobacterium tuberculosis* antigens ESAT-6 and CFP-10 by capturing interferon-gamma (IFN-γ) in the vicinity of T-cells in human whole blood collected in sodium citrate or sodium or lithium heparin. It is intended for use as an aid in the diagnosis of *M tuberculosis* infection. The T-SPOT®.TB test is an indirect test for *M tuberculosis* infection (including disease) and is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluations. Up-to-date product-specific warnings and other information can be found at www.tspot.com

References

1. T-SPOT®.TB [package insert PI-TB-US-0001 V7]. Oxford Immunotec; 2019.
2. Reported tuberculosis in the United States. Centers for Disease Control and Prevention. Reviewed December 31, 2018. Accessed January 9, 2020. <https://www.cdc.gov/tb/default.htm>
3. King TC, Upfal M, Gottlieb A, et al. T-SPOT.TB interferon-γ release assay performance in healthcare worker screening at nineteen US hospitals. *Am J Respir Crit Care Med.* 2015;192(3):367-373. doi:10.1164/rccm.201501-0199OC
4. TB risk factors. Centers for Disease Control and Prevention. Reviewed March 18, 2016. Accessed January 8, 2020. <https://www.cdc.gov/tb/topic/basics/risk.htm>
5. TB 101 for health care workers. Lesson 3: testing for TB infection. Groups at high risk for developing TB disease. Centers for Disease Control and Prevention. Reviewed May 4, 2016. Accessed January 9, 2020. <https://www.cdc.gov/tb/webcourses/tb101/page121.html>
6. Kane SV. Preparing for biologic or immunosuppressant therapy. *Gastroenterol Hepatol.* 2011;7(8):544-546. doi:10.1007/s11894-010-0142-z
7. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res.* 2012;64(5):625-639. doi:10.1002/acr.21641
8. Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. *Am J Gastroenterol.* 2017;112(2):241-258. doi:10.1038/ajg.2016.537
9. Chebli JMF, Gaburri PD, Chebli LA, et al. A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy. *Med Sci Monit.* 2014;20:487-498. doi:10.12659/MSM.890331

The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Test codes may vary by location. Please contact your local laboratory for more information.

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2021 Quest Diagnostics Incorporated. All rights reserved. SB9468 1/2021